Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

FDA Clears Oncomine Dx Target Test as Companion Diagnostic for Sevabertinib in NSCLC

November 20th 2025

The FDA OKs the Oncomine Dx Target Test to identify patients with HER2 TKD–mutant NSCLC eligible for sevabertinib, enabling targeted treatment selection.

FDA Approves Osvyrti and Jubereq in High Fracture Risk Populations, Including in Breast and Prostate Cancer

November 20th 2025

Denosumab-desu (Osvyrti and Jubereq) received FDA approval in the same indications as reference denosumab (Prolia and Xgeva).

Targeting OXPHOS With Lixumistat Could Lessen Chemoresistance in Pancreatic Cancer

November 20th 2025

Shubham Pant, MD, MBBS, and Ryan W. Huey, MD, MS, discuss OXPHOS pathway inhibition in pancreatic cancer with lixumistat.

FDA Approves Daratumumab and Hyaluronidase-fihj in Newly Diagnosed Light Chain Amyloidosis

November 19th 2025

The FDA has granted traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis.

Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma

November 12th 2025

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC

November 12th 2025

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

NALIRIFOX Expands Frontline Options in Metastatic Pancreatic Cancer

November 11th 2025

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

November 8th 2025

Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.

Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer

November 7th 2025

Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.

Phase 3 KEYNOTE-905 and IMvigor011 Trials Signal New Standards in MIBC

November 6th 2025

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC

November 5th 2025

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL

November 4th 2025

In the phase 1 ANTLER study, vispa-cel demonstrated ORRs of 82% and 86% among patients in the confirmatory and optimized cohorts, respectively.

China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC

November 4th 2025

Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.

New ADC Data Underscore Progress and Highlight Challenges in HER2+ Breast Cancer and TNBC Management

November 2nd 2025

In a recent Peer Exchange, breast cancer experts discussed updates from ESMO 2025, including practice-informing data with antibody-drug conjugates.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Tackling Drug Shortages in Hematologic Oncology Care Requires Nuance and Adaptability

October 30th 2025

Harry P. Erba, MD, PhD, and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC

October 29th 2025

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

LEAP-012 Trial of Pembrolizumab/Lenvatinib/TACE to Close Following Missed OS End Point in Unresectable HCC

October 29th 2025

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

ICI Use Does Not Significantly Affect EOL Outcomes in HCC

October 29th 2025

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

Novel Program Aims to Provide Patient-Level Clinical Trial Communication Skills to Hematology/Oncology Fellows

October 28th 2025

Carma L. Bylund, PhD, discussed the findings from a pilot study of a fellowship-level program for clinical trial communication skills.

NEXT PAGE
PREVIOUS PAGE